ADVERTISEMENT

Clinical Summary

5-year survival with pembrolizumab for non-small cell lung cancer

Miriam Davis, PhD   |   14 November 2022

Takeaway

  • The KEYNOTE-042 trial conducted in 32 countries finds 5-year outcomes continuing to favour pembrolizumab monotherapy over platinum-based chemotherapy as first-line therapy for NSCLC.
  • 5-year OS rates with pembrolizumab ranged from 16.6% to 21.9%.
  • Survival benefits occurred regardless of programmed death ligand-1 (PD-L1) tumour proportion score (TPS).

Why this matters

  • Findings...

          

November Challenge

Ends in 1d 6h
left
right

Topic Challenges

left
right